๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changsha
Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Changsha 32
Narrow the registerReset
Recruitment status
Phase
Site location
Changsha32
All 1 locations
Target enrolment
to

Trials with a site in Changsha

32 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
NCT07251582Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
Hunan Province Tumor Hospital
Phase 3
186
Changsha
2026-08-12
Not yet open
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
NCT06706219Non Small Cell Lung Cancer (Stage III)
Hunan Province Tumor Hospital
Phase 2
50
Changsha
2026-05-10
Not yet open
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
NCT07001995Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2026-05-01
Not yet open
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
NCT06828757Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 3
94
Changsha
2025-05-01
Not yet open
Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance
NCT06634667Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2024-11-30
Not yet open
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
NCT06497543Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
80
Changsha
2024-10-01
Not yet open
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
NCT06537297Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2024-09-30
Not yet open
Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
NCT06604351Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
39
Changsha
2024-09-15
Recruiting
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
NCT06348927Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
52
Changsha
2024-07-01
Recruiting
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
NCT06355609Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
100
Changsha
2024-07-01
Recruiting
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
NCT05266846ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy
Hunan Province Tumor Hospital
Phase 2
78
Changsha
2024-05-29
Recruiting
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
NCT06440954Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
220
Changsha
2024-05-01
Recruiting
The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC
NCT06109558Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 1/2
120
Changsha
2023-12-31
Recruiting
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
NCT05991193NSCLC
Hunan Province Tumor Hospital
Observational
100
Changsha
2023-12-29
Recruiting
The Efficacy and Safety of IBI363 in Solid Tumors
NCT06081907Advanced Solid Tumor
DrugIBI363
Hunan Province Tumor Hospital
Phase 1/2
430
Changsha
2023-12-25
Recruiting
JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
NCT04951947Small-cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
30
Changsha
2023-06-01
Recruiting
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
NCT05295212Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
120
Changsha
2023-02-01
Recruiting
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
NCT05584267Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
140
Changsha
2022-12-25
Recruiting
Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement
NCT06073938Advanced Solid Tumors or Lymphomas
Hunan Province Tumor Hospital
Observational
30
Changsha
2022-09-20
Recruiting
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
NCT05379803Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
40
Changsha
2022-05-01
Recruiting
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
NCT05284539Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
760
Changsha
2022-04-01
Recruiting
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
NCT05014464Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
90
Changsha
2021-11-13
Recruiting
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
NCT05059951Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Observational
15,000
Changsha
2021-10-03
Recruiting
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
NCT05055908Lung Cancer
Hunan Province Tumor Hospital
Phase 3
12,000
Changsha
2021-10-01
Recruiting
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
NCT04777084Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2
120
Changsha
2021-08-01
Recruiting
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation
Hunan Province Tumor Hospital
Phase 2
6,000
Changsha
2020-04-16
Recruiting
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
NCT04324151Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Observational
70
Changsha
2020-03-24
Recruiting
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
NCT04322617Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2/3
1,200
Changsha
2020-03-24
Recruiting
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
NCT04324125Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Observational
70
Changsha
2020-03-24
Recruiting
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
NCT04324164Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Observational
800
Changsha
2020-03-24
Recruiting
A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer
NCT06183762Advanced Lung Cancer
Hunan Province Tumor Hospital
Observational
200
Changsha
2020-01-01
Recruiting
Survival Outcomes of Lung Cancer
NCT03647098Lung Cancer
Hunan Province Tumor Hospital
Observational
20,000
Changsha
2018-08-01
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/changsha

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Changsha that also match the filters currently applied.

How many clinical trials are recruiting in Changsha?

25 of the 32 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changsha), 32 studies
PhaseStudiesRecruitingShare
Phase 2181256.3%
Observational8825%
Phase 3329.4%
Phase 1/2226.3%
Phase 2/3113.1%

Most active sponsors

Lead sponsors with the most studies (Changsha)
Lead sponsorStudiesRecruiting
Hunan Province Tumor Hospital3225
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.